We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us


Beckman Coulter develops, manufactures and markets laboratory systems, reagents, centrifugation, lab automation, elec... read more Featured Products: More products

Download Mobile App

Beckman Coulter and MeMed Expand Host Immune Response Diagnostics Partnership

By LabMedica International staff writers
Posted on 10 May 2024
Print article
Image: Beckman Coulter is now an authorized distributor of the MeMed Key immunoassay system and MeMed BV assay (Photo courtesy of Beckman Coulter)
Image: Beckman Coulter is now an authorized distributor of the MeMed Key immunoassay system and MeMed BV assay (Photo courtesy of Beckman Coulter)

Beckman Coulter Diagnostics (Brea, CA, USA) and MeMed BV (Haifa, Israel) have expanded their host immune response diagnostics partnership. Beckman Coulter is now an authorized distributor of the MeMed BV assay, a rapid immunoassay test that can differentiate between bacterial and viral infections, and MeMed Key, a compact immunoassay analyzer which is cleared to run the MeMed BV assay in the United States and Europe. The latest distribution agreement complements the existing joint effort by both companies to develop a MeMed BV-based test for Beckman Coulter's family of Access Immunoassay Analyzers.

Differentiating between bacterial and viral infections can often be challenging for physicians due to similar presenting symptoms, leading to potential misuse of antibiotics. The MeMed BV test, employing a machine learning algorithm, combines measurements of three critical immune response proteins (TRAIL, IP-10, and CRP) to indicate the likelihood of bacterial versus viral infections. This test’s efficacy has been confirmed through extensive validation studies internationally and is now gaining traction in clinical settings across the U.S. and Europe, with over 20,000 patients tested.

Recent studies have indicated that in about 29% of cases, clinicians encounter difficulties in distinguishing between bacterial and viral infections, which can delay effective decision-making and disrupt diagnostic processes. The MeMed BV assay has been shown to influence or change physician decisions in 87% of cases, demonstrating its significant impact on clinical practices (p < 0.05). The test delivers results within 15 minutes using serum or whole blood and has a greater than 99% negative predictive value for excluding bacterial infections.

"Beckman Coulter's commitment to improving infection management is unwavering," said Kevin O'Reilly, President, Beckman Coulter. "To that end, we are excited to extend our partnership with MeMed by expanding market access to the MeMed Key and BV assay. These MeMed innovations complement Beckman Coulter's portfolio of host response diagnostics, including our CBC-based hematological biomarker MDW [monocyte distribution width] identifying the presence of severe infection and risk of sepsis, our clinical chemistry PCT [procalcitonin] assay aiding risk assessment for septic shock, and our full suite of microbiology solutions providing faster time to optimize antibiotic therapies."

"We're excited to expand our partnership with Beckman Coulter, taking an additional step forward in our shared mission to advance pioneering host-response solutions,” added Dr. Eran Eden, MeMed's CEO and co-founder. “This expansion focuses on two main objectives: first, to educate and prime the market to accelerate the adoption of MeMed BV once it's cleared for use on Beckman Coulter's core-lab immunoassay analyzers; second, to broaden patient access to MeMed BV through a strategic hub and spoke model. By combining the capabilities of Beckman Coulter's analyzers with the MeMed Key's ability to deliver results directly from whole blood within minutes, we're creating a synergistic ecosystem that aids clinicians in distinguishing between bacterial and viral infections with unprecedented ease and precision."

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
POCT Fluorescent Immunoassay Analyzer
Gold Member
Magnetic Bead Separation Modules

Print article


Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more


view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more


view channel
Image: The novel test uses an existing diagnostic procedure as its basis to target the Epstein Barr Virus (Photo courtesy of 123RF)

Blood Test Measures Immune Response to Epstein-Barr Virus in MS Patients

Multiple sclerosis (MS) is a chronic neurological condition for which there is currently no cure. It affects around three million people globally and ranks as the second most common cause of disability... Read more


view channel
Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock)

Integrated Solution Ushers New Era of Automated Tuberculosis Testing

Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more


view channel
Image: Insulin proteins clumping together (Photo courtesy of Jacob Kæstel-Hansen)

AI Tool Detects Tiny Protein Clumps in Microscopy Images in Real-Time

Over 55 million individuals worldwide suffer from dementia-related diseases like Alzheimer's and Parkinson's. These conditions are caused by the clumping together of the smallest building blocks in the... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.